Relative effectiveness of bivalent Original/Omicron BA.4-5 mRNA vaccine in preventing severe COVID-19 in persons 60 years and above during SARS-CoV-2 Omicron XBB.1.5 and other XBB sublineages circulation, Italy, April to June 2023

During predominant circulation of SARS-CoV-2 Omicron XBB.1.5 and other XBB sublineages (April–June 2023), we found that a second or third booster of Comirnaty bivalent Original/Omicron BA.4-5 mRNA vaccine, versus a first booster received at least 120 days earlier, was effective in preventing severe...

Descripción completa

Detalles Bibliográficos
Autores principales: Fabiani, Massimo, Mateo-Urdiales, Alberto, Sacco, Chiara, Rota, Maria Cristina, Fotakis, Emmanouil Alexandros, Petrone, Daniele, Del Manso, Martina, Siddu, Andrea, Stefanelli, Paola, Bella, Antonino, Riccardo, Flavia, Rezza, Giovanni, Palamara, Anna Teresa, Brusaferro, Silvio, Pezzotti, Patrizio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Centre for Disease Prevention and Control (ECDC) 2023
Materias:
Rapid Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10416574/
https://www.ncbi.nlm.nih.gov/pubmed/37561053
http://dx.doi.org/10.2807/1560-7917.ES.2023.28.32.2300397

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10416574/
https://www.ncbi.nlm.nih.gov/pubmed/37561053
http://dx.doi.org/10.2807/1560-7917.ES.2023.28.32.2300397

Ejemplares similares